← ANALYST RATINGS · TIPRANKS
CVRx (CVRX): analyst forecast and price target
Analyst consensus
Moderate Buy3 Buy3 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $4.38, the highest $5.00, the lowest $3.50. The average is +236.5% from the last price of $1.30.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $1.50 → $1.00−33.3% | Sell | −23.1% | Downgrade | 17.10.26on TipRanks 07:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $1.50 → $1.00−33.3% | Sell | −23.1% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $1.50 → $1.00−33.3% | Sell | −23.1% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 → $1.00−33.3% | Hold | −23.1% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $1.50 → $1.00−33.3% | Sell | −23.1% | Reiterated | 15.10.26on TipRanks 17:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $2.50 → $1.50−40.0% | Hold | +15.4% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | — | Hold | — | Reiterated | 22.09.26on TipRanks 13:40 | −2.7%next day −5.2% · 5 days −7.8% | ↗ |
| Frank Takkinen★★★★★★★★★★#11823 · hits 38% · avg −3.6% | Lake Street | $3.50 | Hold | +169.2% | Reiterated | 22.09.26on TipRanks 09:10 | −2.7%next day −5.2% · 5 days −7.8% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $4.00 | Hold | +207.7% | Reiterated | 22.09.26on TipRanks 07:10 | −2.7%next day −5.2% · 5 days −7.8% | ↗ |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $5.00 | Buy | +284.6% | Reiterated | 21.09.26on TipRanks Sep 22 07:55 | −3.9%next day −2.7% · 5 days −11.8% | ↗ |
| Sarah James★★★★★★★★★★#2265 · hits 55% · avg +5.7% | Cantor Fitzgerald | $13.00 → $5.00−61.5% | Buy | +284.6% | Reiterated | 17.08.26on TipRanks 08:27 | −10.2%next day +0.7% · 5 days +15.7% | ↗ |
| Brandon Vazquez★★★★★★★★★★#11688 · hits 42% · avg −5.1% | William Blair | — | Buy | — | Reiterated | 07.08.26on TipRanks 02:35 | −60.4%next day −0.8% · 5 days +28.5% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $6.00 | Sell | +361.5% | Reiterated | 12.05.26on TipRanks 07:40 | −23.7%next day −1.5% · 5 days +14.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering CVRx
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $4.38 at a price of $1.75 (+150.0%); now: $4.38 at $1.30 (+236.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 6 | 5 |
| Buy | 5 | 8 | 6 | 5 | 2 | 1 |
| Hold | 0 | 0 | 0 | 4 | 7 | 7 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.50 (from $-0.53 to $-0.47). Last quarter: $-0.53.
Sales
Next quarter’s sales estimate — $14M (from $14M to $14M). Last quarter: $16M.
Best top-analyst consensus in the sector · Healthcare
About CVRx
- CEO: Kevin Hykes
- Employees: 223
- 9201 West Broadway Avenue, Minneapolis, MN, 55445, US
- www.barostim.com
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Data from the stock’s TipRanks forecast page, read 47 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗